Acadian Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Acadian Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1M	Buy	62,838 +8,024	+15%	+$1.76M	0.02%	482
2026 Q1	$10.4M	Buy	54,814 +53,127	+3,149%	+$9.28M	0.01%	527
2025 Q4	$286K	Buy	+1,687	New	+$259K	﹤0.01%	1444
2025 Q2	–	Sell	-730	Closed	-$90K	–	1744
2025 Q1	$90K	Buy	+730	New	+$95.2K	﹤0.01%	1366
2021 Q3	–	Sell	-100,021	Closed	-$17.8M	–	1851
2021 Q2	$17.8M	Sell	100,021 -78,113	-44%	-$13.5M	0.07%	231
2021 Q1	$29.3M	Sell	178,134 -60,455	-25%	-$9.95M	0.11%	173
2020 Q4	$39.4M	Sell	238,589 -129,256	-35%	-$19.3M	0.15%	130
2020 Q3	$52.4M	Sell	367,845 -93,676	-20%	-$11.6M	0.22%	102
2020 Q2	$50.9M	Buy	461,521 +33,697	+8%	+$3.73M	0.22%	115
2020 Q1	$42.7M	Sell	427,824 -38,490	-8%	-$4.98M	0.24%	104
2019 Q4	$69.6M	Sell	466,314 -55,964	-11%	-$7.62M	0.32%	79
2019 Q3	$66.9M	Buy	522,278 +39,597	+8%	+$5.31M	0.29%	92
2019 Q2	$68.8M	Buy	482,681 +33,929	+8%	+$4.56M	0.33%	82
2019 Q1	$64.1M	Buy	448,752 +44,572	+11%	+$5.81M	0.28%	94
2018 Q4	$50.1M	Buy	404,180 +111,961	+38%	+$16.6M	0.25%	108
2018 Q3	$49.1M	Buy	292,219 +127,694	+78%	+$22M	0.2%	113
2018 Q2	$28.3M	Buy	164,525 +134,154	+442%	+$21.9M	0.12%	156
2018 Q1	$4.58M	Buy	30,371 +12,960	+74%	+$1.9M	0.02%	414
2017 Q4	$2.34M	Buy	17,411 +17,363	+36,173%	+$2.41M	0.01%	525
2017 Q3	$7K	Sell	48 -523	-92%	-$79.1K	﹤0.01%	1302
2017 Q2	$88K	Sell	571 -28	-5%	-$4.28K	﹤0.01%	1045
2017 Q1	$87K	Sell	599 -6,769	-92%	-$882K	﹤0.01%	1150
2016 Q4	$804K	Sell	7,368 -10,999	-60%	-$1.23M	﹤0.01%	761
2016 Q3	$2.23M	Sell	18,367 -53,048	-74%	-$7.15M	0.01%	520
2016 Q2	$10.1M	Buy	71,415 +69,989	+4,908%	+$10.3M	0.05%	262
2016 Q1	$186K	Buy	+1,426	New	+$178K	﹤0.01%	935
2015 Q4	–	Sell	-910	Closed	-$121K	–	1457
2015 Q3	$121K	Buy	+910	New	+$157K	﹤0.01%	962

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Acadian Asset Management's JAZZ Position: Q2 2026 in Review

Acadian Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 15% in Q2 2026, buying an estimated $1.76M and bringing the position to 62,838 shares worth $15.1M. The position accounts for 0.02% of the portfolio, ranked #482.

Acadian Asset Management first reported a position in JAZZ in Q3 2015 and has held it in 27 quarters since. The position peaked at $69.6M in Q4 2019. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Acadian Asset Management held 62,838 shares of Jazz Pharmaceuticals worth $15.1M as of Q2 2026.
Acadian Asset Management bought 8,024 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
Jazz Pharmaceuticals made up 0.02% of Acadian Asset Management's portfolio in Q2 2026, its #482 holding.
Acadian Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2015 and has held it in 27 quarters since.
Acadian Asset Management's Jazz Pharmaceuticals position peaked at $69.6M in Q4 2019.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.